Biaryl compounds having anti-infective activity

• US 7,498,349 B2
• Filed: 08/01/2003
• Issued: 03/03/2009
• Est. Priority Date: 08/02/2002
• Status: Expired due to Fees

• Current Assignee: Genesoft Pharmaceuticals, Inc. (Oscient Pharmaceuticals Corporation)
• Original Assignee: Genesoft Pharmaceuticals, Inc. (Oscient Pharmaceuticals Corporation)
• Inventors: McMinn, Dustin L., Kaizerman, Jacob A., Baird, Eldon E., Burli, Roland W.
• Primary Examiner(s): Saeed; Kamal A
• Assistant Examiner(s): NOLAN, JASON MICHAEL
• Application Number:
  US10/523,422
• Publication Number:
  US 20060128747A1
• Time in Patent Office: 2,041 Days
• Field of Search: 514/302, 514/333, 514/339, 514/337, 514/338, 514/372, 514/469, 546/115, 546/256, 546/277.4, 546/281.1, 546/284.1, 548/206, 548/214, 549/469
• US Class Current: 514/333
• CPC Class Codes: A61K 31/44 Non condensed pyridines; Hydrogenated derivatives thereof
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: C07D 307/81 Radicals substituted by nitrogen atoms not forming part of a nitro radical
• CPC Class Codes: C07D 401/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 405/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 405/14 containing three or more hetero rings
• CPC Class Codes: C07D 409/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 409/14 containing three or more hetero rings
• CPC Class Codes: C07D 417/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 417/14 containing three or more hetero rings

Abstract

Aromatic compounds exemplified by exhibit antimicrobial activity.

Claims

1. A compound according to the formula

2. A compound according to claim 1, wherein at least one group R² contains an alkyl amine group.

3. A compound according to claim 1 or 2, wherein

4. A compound according to claim 1 or 2, wherein

5. A compound according to claim 1 or 2, wherein

6. A compound according to claim 1 or 2, wherein R³ is H.

8. A compound according to claim 1, 2 or 7, wherein N(R²)₂ is selected from the group consisting of

9. A compound according to claim 1, having a minimum inhibitory concentration of 4 μ

g/mL or less against at least one of Staphylococcus aureus (ATCC

     27660), Streptococcus pneumoniae (ATCC

     51422), and Enterococcus faecium (ATCC

     51559).

10. A method of treating a Gram-positive bacterial infection in a mammal, comprising administering to a patient in need of such treatment an effective amount of a compound according to claim 1, 2, or 7.

11. A method according to claim 10, wherein the bacterial infection is an infection by drug resistant bacteria.

12. A method according to claim 11, wherein the drug resistant bacteria is MRSA, PRSP, or VRE.

13. A compound according to claim 1, wherein R¹ is H or CH₃.

7. A compound according to a formula selected from the group consisting of